Literature DB >> 21555616

Advancing the treatment of conjunctival scarring: a novel ex vivo model.

Victoria E Tovell1, Annegret H Dahlmann-Noor, Peng T Khaw, Maryse Bailly.   

Abstract

OBJECTIVES: To develop and validate a novel ex vivo model of conjunctival contraction.
METHODS: Ex vivo segments of conjunctiva were maintained in culture for 4 weeks in permeable support plates. Digital images were obtained twice a week to monitor contraction using tissue area changes and weekly weight measurements. Investigated were the effects of known contraction stimulators (fetal bovine serum and transforming growth factor β(2)) and of the matrix metalloproteinase inhibitor GM6001. Microscopic contraction, tissue organization, and cell viability (using the cell vital dye carboxyfluorescein diacetate) were monitored by confocal reflection and 2-photon microscopy, revealing detailed real-time kinetics of tissue remodeling.
RESULTS: Fetal bovine serum and transforming growth factor β(2) induced significant tissue contraction in conjunctiva segments, with no changes in cell viability. This correlated with dramatic and specific degradation of the collagen component in the tissue. Contraction and collagen degradation were reduced in the presence of GM6001.
CONCLUSIONS: Ex vivo segments of conjunctiva can be used as an integral model system to provide a higher level of understanding about the efficacy of antiscarring therapies and can help bridge the current gap between in vitro and in vivo models. CLINICAL RELEVANCE: Scarring leads to the failure of several ocular surgical procedures. This novel ex vivo model recapitulates tissue contraction (with kinetics close to that of in vivo scarring) and allows for a more physiological analysis of conjunctival scarring, which could better evaluate potential therapeutic targets.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21555616      PMCID: PMC7611858          DOI: 10.1001/archophthalmol.2011.91

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  29 in total

1.  Internet-based image analysis quantifies contractile behavior of individual fibroblasts inside model tissue.

Authors:  Steven Vanni; B Christoffer Lagerholm; Carol Otey; D Lansing Taylor; Frederick Lanni
Journal:  Biophys J       Date:  2003-04       Impact factor: 4.033

2.  Microstructural mechanics of collagen gels in confined compression: poroelasticity, viscoelasticity, and collapse.

Authors:  Preethi L Chandran; Victor H Barocas
Journal:  J Biomech Eng       Date:  2004-04       Impact factor: 2.097

3.  Production of a tissue-like structure by contraction of collagen lattices by human fibroblasts of different proliferative potential in vitro.

Authors:  E Bell; B Ivarsson; C Merrill
Journal:  Proc Natl Acad Sci U S A       Date:  1979-03       Impact factor: 11.205

4.  TGF-beta1, -beta2, and -beta3 in vitro: biphasic effects on Tenon's fibroblast contraction, proliferation, and migration.

Authors:  M F Cordeiro; S S Bhattacharya; G S Schultz; P T Khaw
Journal:  Invest Ophthalmol Vis Sci       Date:  2000-03       Impact factor: 4.799

5.  Antimetabolite-induced apoptosis in Tenon's capsule fibroblasts.

Authors:  J G Crowston; A N Akbar; P H Constable; N L Occleston; J T Daniels; P T Khaw
Journal:  Invest Ophthalmol Vis Sci       Date:  1998-02       Impact factor: 4.799

Review 6.  Current and future prospects for the prevention of ocular fibrosis.

Authors:  Annegret H Dahlmann; Kamiar Mireskandari; Alison D Cambrey; Maryse Bailly; Peng Tee Khaw
Journal:  Ophthalmol Clin North Am       Date:  2005-12

7.  Matrix metalloproteinase inhibition modulates fibroblast-mediated matrix contraction and collagen production in vitro.

Authors:  Julie T Daniels; Alison D Cambrey; Nicholas L Occleston; Qian Garrett; Roy W Tarnuzzer; Gregory S Schultz; Peng T Khaw
Journal:  Invest Ophthalmol Vis Sci       Date:  2003-03       Impact factor: 4.799

8.  Effects of single exposures to antiproliferative agents on ocular fibroblast-mediated collagen contraction.

Authors:  N L Occleston; R A Alexander; A Mazure; G Larkin; P T Khaw
Journal:  Invest Ophthalmol Vis Sci       Date:  1994-09       Impact factor: 4.799

Review 9.  Fibroblasts, myofibroblasts, and wound contraction.

Authors:  F Grinnell
Journal:  J Cell Biol       Date:  1994-02       Impact factor: 10.539

10.  Porcine sclera as a model of human sclera for in vitro transport experiments: histology, SEM, and comparative permeability.

Authors:  S Nicoli; G Ferrari; M Quarta; C Macaluso; P Govoni; D Dallatana; P Santi
Journal:  Mol Vis       Date:  2009-02-06       Impact factor: 2.367

View more
  9 in total

1.  Assessment of progressive alterations in collagen organization in the postoperative conjunctiva by multiphoton microscopy.

Authors:  Li-Fong Seet; Stephanie W L Chu; Xiao Teng; Li Zhen Toh; Tina T Wong
Journal:  Biomed Opt Express       Date:  2020-10-19       Impact factor: 3.732

2.  Doxycycline prevents matrix remodeling and contraction by trichiasis-derived conjunctival fibroblasts.

Authors:  He Li; Daniel G Ezra; Matthew J Burton; Maryse Bailly
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-07-12       Impact factor: 4.799

3.  Activation of Rac by Asef2 promotes myosin II-dependent contractility to inhibit cell migration on type I collagen.

Authors:  Léolène Jean; Devi Majumdar; Mingjian Shi; Louis E Hinkle; Nicole L Diggins; Mingfang Ao; Joshua A Broussard; J Corey Evans; David P Choma; Donna J Webb
Journal:  J Cell Sci       Date:  2013-10-21       Impact factor: 5.285

Review 4.  Molecular mechanisms and treatments for ocular symblephara.

Authors:  Aditi Swarup; Christopher N Ta; Albert Y Wu
Journal:  Surv Ophthalmol       Date:  2021-04-29       Impact factor: 6.048

5.  An Ilomastat-CD Eye Drop Formulation to Treat Ocular Scarring.

Authors:  Abeer H A Mohamed-Ahmed; Alastair Lockwood; He Li; Maryse Bailly; Peng T Khaw; Steve Brocchini
Journal:  Invest Ophthalmol Vis Sci       Date:  2017-07-01       Impact factor: 4.799

6.  Local delivery of novel MRTF/SRF inhibitors prevents scar tissue formation in a preclinical model of fibrosis.

Authors:  Cynthia Yu-Wai-Man; Bradley Spencer-Dene; Richard M H Lee; Kim Hutchings; Erika M Lisabeth; Richard Treisman; Maryse Bailly; Scott D Larsen; Richard R Neubig; Peng T Khaw
Journal:  Sci Rep       Date:  2017-03-31       Impact factor: 4.379

7.  SPARC Levels Modulate the Capacity of Mitomycin to Inhibit the Proliferation of Human Tenon's Capsule Fibroblasts.

Authors:  Yuanyuan Guo; Shouxiang Ni; Weiyan Zhou; Jiangping Hou; Jiaquan Shen
Journal:  J Ophthalmol       Date:  2020-02-10       Impact factor: 1.909

8.  Eyelid and Sternum Fibroblasts Differ in Their Contraction Potential and Responses to Inflammatory Cytokines.

Authors:  He Li; Jonathan C P Roos; Geoffrey E Rose; Maryse Bailly; Daniel G Ezra
Journal:  Plast Reconstr Surg Glob Open       Date:  2015-08-10

9.  A Tenon's capsule/bulbar conjunctiva interface biomimetic to model fibrosis and local drug delivery.

Authors:  Katarzyna Kozdon; Bruna Caridi; Iheukwumere Duru; Daniel G Ezra; James B Phillips; Maryse Bailly
Journal:  PLoS One       Date:  2020-11-03       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.